New Guidelines Issued for Head and Neck Cancer Survivor Care
March 28th 2016The American Cancer Society has issued a new clinical practice guideline for the follow-up screening and care coordination for this population of survivors, who may experience significant physical, psychosocial, and practical effects from their cancer and its treatment.
Symptom Burden Higher in Newly Diagnosed Patients Reporting Financial Strain
March 25th 2016A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.
Extended-Release Anti-CINV Agent Effective in Patients Treated With Cisplatin
March 22nd 2016Findings from a randomized trial reported at the 2016 Annual Meeting of the Society of Gynecologic Oncology showed that APF530, an extended-release formulation of the antiemetic granisetron, achieved a complete response more often than did ondansetron in patients receiving highly emetogenic cisplatin-based chemotherapy.
Neurofeedback Relieves Pain of Chemotherapy-Induced Peripheral Neuropathy
March 19th 2016A majority of patients with cancer who undergo chemotherapy experience neuropathy as result of the treatment, and a new study conducted by researchers at The University of Texas MD Anderson Cancer Center suggests that neurofeedback can reduce the pain associated with the condition and improve quality of life.
GMA Anchor Amy Robach on Breast Cancer Screening and Survival
March 14th 2016Drawing a standing ovation from a packed room of oncology professionals attending the 33rd Annual Miami Breast Cancer Conference®, breast cancer survivor and Good Morning America news anchor Amy Robach criticized new US Preventive Services Task Force guidelines that extend the recommended age to begin mammogram screening to age 50 for women at average risk.
ASCO Issues New Guidelines for Biomarker Use in Breast Cancer
March 9th 2016The American Society of Clinical Oncology convened a panel of experts to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer.
FDA Expands Ibrutinib for Use in Previously Untreated Patients With CLL
March 9th 2016An impressive improvement in progression-free survival (PFS) in the RESONATE-2 trial led to the FDA’s approval of ibrutinib (Imbruvica) March 4 for the frontline treatment of chronic lymphocytic leukemia, based on data from the RESONATE-2 trial.
More Evidence That Breast Cancer Survivors Should Stop Smoking
March 7th 2016The first study to assess smoking habits of women with breast cancer before and after diagnosis has found that those who quit smoking after their diagnosis had a 33% lower risk of dying of the disease than those who continued to smoke.
3D Mammograms Improve Breast Cancer Detection, Reduce Callbacks
March 4th 2016The benefits of 3D mammography are durable, increasing detection of breast cancers and reducing anxiety over callbacks, according to a recent study that provides the first longitudinal evidence of the utility of this approach.